Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebral function in chronic hepatitis C patients treated with pegylated interferon alfa-2a and ribavirin
2007-005707-18Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Jun 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection, sponsored by Aarhus University Hospital. Primary endpoint: Cognitive function and neuropsychological outcomes. Started Jun 2008; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-005707-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005707-18.